Zacks Investment Research on MSN10d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Medical Marketing & Media4d
Novo Nordisk welcomes patients to the Ozempic Era
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Biznews10d
🔒 Novo’s insulin pen phase-out sparks CompCom probe as diabetes remains a silent killer among SA women
South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.
How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...
Novo Nordisk A/S (NYSE:NVO): A Strong Pipeline to Aid Recovery
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...